drugset / Trial / NCT05443464
Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objective of this clinical study is to demonstrate safety and feasibility of single-dose infusion of Ossium MSCs product (OSSM-001) to treat steroid refractory acute GVHD (SR-aGVHD).
Timeline
- Start
- 2023-06-05
- Primary completion
- 2024-06-10
- Completion
- 2024-10-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesenchymal stem cell | Cell therapy | 2 cells/kg | Intravenous |
| Subject | Mesenchymal stem cell | Cell therapy | 6 cells/kg | Intravenous |
| Subject | Mesenchymal stem cell | Cell therapy | 12 cells/kg | Intravenous |
| Subject | Mesenchymal stem cell | Cell therapy | 24 cells/kg | Intravenous |